EU/3/18/1981

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1981) was granted by the European Commission to Midatech Pharma Plc, United Kingdom, for mertansine functionalised gold nanoconjugate for the treatment of hepatocellular carcinoma.

Key facts

Active substance
Mertansine functionalised gold nanoconjugate
Disease / condition
Treatment of hepatocellular carcinoma
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1981

Sponsor's contact details

Midatech Pharma Plc - United Kingdom
65 Innovation Drive
Milton Park
Abingdon
OX14 4RQ
United Kingdom
Tel. 44 (0)1235 888300
E-mail: info@midatechpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating